Search Results

You are looking at 221 - 230 of 2,748 items for :

  • Refine by Access: All x
Clear All
Full access

HSR23-114: Clinical Characteristics and Outcomes of US Extensive Stage Small Cell Lung Cancer (ES-SCLC) Patients Not Receiving Guideline Preferred Regimens

Daniel Simmons, Yang Xiao, Corina Roca, Zhuoxin Jiang, and Marnie Boron

-preferred regimens and describe their outcomes. Methods: We conducted a retrospective observational cohort study using US electronic health records from Flatiron Health. Patients were diagnosed with ES-SCLC between October 1st 2018 and June 30th 2022 and were

Full access

CLO23-042: Clinical Outcomes of Radical Radiotherapy With or Without Chemotherapy in Inoperable Locally Advanced Squamous Cell Carcinoma of Oral Cavity

Maria Philip, Jomon Raphael Chalissery, Febin Antony, Rajkrishna B, and Mathew Varghese K

to determine the benefits and overall survival in these patients treated with definitive radiotherapy with or without concurrent chemotherapy. Methods: We conducted a retrospective analysis to evaluate the clinical outcomes in patients with

Full access

HSR22-166: Patient Demographic and Socioeconomic Differences in Non-Small Cell and Small Cell Lung Cancers: Impact on Outcomes. A National Cancer Database Analysis.

Logan Roof, Wei Wei, and James P Stevenson

communities, distance to an academic center, income, insurer, and education level. The goal of this study was to determine whether the same disparities exist in non-small cell lung cancer (NSCLC), and how the patient demographics and outcomes compare to those

Full access

EPR22-111: Outcomes and Utilization of Adjuvant Chemotherapy With and Without an Anthracycline in Node-Positive, Triple-Negative Breast Cancer: Analysis of SEER-Medicare Data

Stephanie Lakritz, Anna Schreiber, Elizabeth Molina, Elisabeth Meyer, Cathy J Bradley, and Jennifer R Diamond

therapy (ATAX) regimens shown to be more efficacious compared to non-anthracycline-containing, taxane-based regimens (TAX) in node-positive disease. However, data investigating outcomes and utilization of adjuvant chemotherapy in older women with node

Full access

Multigene Sets for Clinical Application in Glioma

John F. de Groot, Erik P. Sulman, and Kenneth D. Aldape

proliferation and necrosis. 1 Although histologic classification allowed patients with a single disease to be enrolled into clinical trials, and treatment protocols for these patients to be standardized, 2 outcomes were variable and could not be attributed to

Full access

Phase II Trial of Symptom Screening With Targeted Early Palliative Care for Patients With Advanced Cancer

Camilla Zimmermann, Ashley Pope, Breffni Hannon, Monika K. Krzyzanowska, Gary Rodin, Madeline Li, Doris Howell, Jennifer J. Knox, Natasha B. Leighl, Srikala Sridhar, Amit M. Oza, Rebecca Prince, Stephanie Lheureux, Aaron R. Hansen, Anne Rydall, Brittany Chow, Leonie Herx, Christopher M. Booth, Deborah Dudgeon, Neesha Dhani, Geoffrey Liu, Philippe L. Bedard, Jean Mathews, Nadia Swami, and Lisa W. Le

—Symptom screening with Targeted Early Palliative care (STEP)—for patients with advanced cancer. Secondary aims were to assess whether STEP identified patients with worse QoL and other patient-reported outcomes (PROs), and whether screen-positive patients who

Full access

The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids

Neil J. Shah, Michael R. Cook, Tianmin Wu, Shaked Lev-Ari, Matthew J. Blackburn, Michael T. Serzan, Adil Alaoui, Jaeil Ahn, and Michael B. Atkins

equivalent for >4 weeks receive antimicrobial prophylaxis for Pneumocystis jirovecii pneumonia (PJP). Limited data exist regarding the incidence and outcome of OIs among patients receiving ICIs who need SS and/or ISAs for >4 weeks to manage irAEs

Full access

The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement

Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes, and Douglas E. Wood

scan. Outcomes would be expected to differ significantly between these groups. Andre et al. 5 retrospectively analyzed data on 702 consecutive patients with N2 disease at 6 French centers and found that the degree of N2 involvement correlated with

Full access

Predictive Biomarkers for Anti-Epidermal Growth Factor Receptor Therapy: Beyond KRAS Testing

Noman Ashraf, Nishi Kothari, and Richard Kim

agents and targeted therapies against both vascular endothelial growth factor and epidermal growth factor receptor (EGFR), survival has improved. However, outcomes remain highly variable because CRC is a heterogeneous multipathway disease. 2 , 3 It is

Full access

Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy

Douglas W. Blayney, Nicole M. Kuderer, Alice Kate Cummings Joyner, John Jarvis, Dominic Nunag, Jasmine Wells, Lan Huang, Ramon Monhanlal, and Gary H. Lyman

immediately preceding the index date, and included patient demographics, comorbidities, and healthcare resource utilization. To investigate the real-world protective benefit of PP G-CSFs, proportions of patients experiencing the primary outcome of FN or